Pelvis Adaptive Radiotherapy (ART)
Pelvis Adaptive Radiation Therapy
Royal North Shore Hospital
280 participants
Oct 9, 2025
INTERVENTIONAL
Conditions
Summary
Pelvis Adaptive radiotherapy (ART) is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for cancer patients having radiotherapy in the pelvic region. Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced. Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Phase 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for patients with cancer in the pelvic area.
Eligibility
Inclusion Criteria11
- Age \> 18
- ECOG performance status 0-2
- Patients receiving curative or adjuvant pelvic radiation including:
- Prostate cancer where nodal treatment is required
- Prostate cancer post prostatectomy
- Bladder cancer
- Rectal cancer
- Anal cancer
- Adjuvant radiotherapy for gynaecological cancers
- Pelvic Lymph nodes only
- Ability to understand and the willingness to sign an informed consent
Exclusion Criteria2
- Hip prosthesis
- Patient separation from approximate radiation centre to skin edge \> 24cm, measured on diagnostic scan
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06650033